Prothena (PRTA) Competitor Comparison
We are evaluating the key criteria listed to compare Prothena (PRTA) against its competitors in the Biotechnology industry.
Market Capitalization
94 / 368Gross Profits
227 / 278Total Revenue
78 / 300EBITDA
218 / 337Free Cashflow
95 / 352Quick Ratio
59 / 357Earnings per Share
127 / 359Dividend yield
0 / 6Total Cash
42 / 358Performance 3 years
203 / 368Performance 5 years
78 / 368Performance 10 years
119 / 368Linearity 3 years
113 / 368Linearity 5 years
40 / 368Linearity 10 years
13 / 368Total Rank
348 / 368Dividend Rank
248 / 368Valuation Rank
225 / 368Piotroski Rank
305 / 368Muliplier Rank
184 / 368Performance 3 years - PRTA ranking 203 / 368
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.